search
Back to results

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Primary Purpose

Leukemia, Lymphoma, Lymphoproliferative Disorder

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
anti-thymocyte globulin
donor lymphocytes
filgrastim
therapeutic allogeneic lymphocytes
busulfan
fludarabine phosphate
methotrexate
mycophenolate mofetil
tacrolimus
reduced-intensity transplant conditioning procedure
allogeneic hematopoietic stem cell transplantation
peripheral blood stem cell transplantation
Sponsored by
Alliance for Clinical Trials in Oncology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leukemia focused on measuring adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), juvenile myelomonocytic leukemia, prolymphocytic leukemia, recurrent adult acute myeloid leukemia, recurrent adult T-cell leukemia/lymphoma, recurrent childhood acute myeloid leukemia, refractory chronic lymphocytic leukemia, recurrent adult Hodgkin lymphoma, recurrent adult Burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade III lymphomatoid granulomatosis, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent childhood grade III lymphomatoid granulomatosis, recurrent childhood large cell lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent childhood small noncleaved cell lymphoma, recurrent cutaneous T-cell non-Hodgkin lymphoma, recurrent mycosis fungoides/Sezary syndrome, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, recurrent/refractory childhood Hodgkin lymphoma, childhood diffuse large cell lymphoma, childhood grade III lymphomatoid granulomatosis, childhood immunoblastic large cell lymphoma, childhood nasal type extranodal NK/T-cell lymphoma, post-transplant lymphoproliferative disorder, stage I multiple myeloma, stage II multiple myeloma, stage III multiple myeloma, refractory multiple myeloma, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, childhood myelodysplastic syndromes, recurrent childhood anaplastic large cell lymphoma, adult acute myelomonocytic leukemia (M4), childhood acute myelomonocytic leukemia (M4), adult acute minimally differentiated myeloid leukemia (M0), childhood acute minimally differentiated myeloid leukemia (M0), adult acute myeloblastic leukemia without maturation (M1), childhood acute myeloblastic leukemia without maturation (M1), adult acute myeloblastic leukemia with maturation (M2), childhood acute myeloblastic leukemia with maturation (M2), adult acute promyelocytic leukemia (M3), childhood acute promyelocytic leukemia (M3), adult acute monoblastic leukemia (M5a), adult acute monocytic leukemia (M5b), childhood acute monoblastic leukemia (M5a), childhood acute monocytic leukemia (M5b), adult erythroleukemia (M6a), adult pure erythroid leukemia (M6b), childhood acute erythroleukemia (M6), adult acute megakaryoblastic leukemia (M7), childhood acute megakaryocytic leukemia (M7), childhood Burkitt lymphoma, atypical chronic myeloid leukemia, BCR-ABL1 negative, chronic myelomonocytic leukemia, cutaneous B-cell non-Hodgkin lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma, myelodysplastic/myeloproliferative neoplasm, unclassifiable

Eligibility Criteria

undefined - 69 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS:

  • Histologically confirmed hematologic malignancies:

    • Chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL)

      • Absolute lymphocytosis of > 5,000/μL

      • Lymphocytes must appear morphologically mature with < 55% prolymphocytes (CLL)

        • Patients with > 55% prolymphocytes are considered as having PLL
      • Lymphocyte phenotype with expression of CD20, CD19, and CD5 (CLL)

    • Non-Hodgkin lymphoma

      • Any WHO classification of histologic subtype
      • Core biopsies acceptable for primary diagnosis and immunophenotyping
      • Bone marrow biopsies as sole means of diagnosis not allowed for follicular lymphoma

    • Hodgkin lymphoma

      • Any WHO classification of histologic subtype
      • Core biopsies acceptable for primary diagnosis and immunophenotyping
      • Bone marrow biopsy is required

    • Multiple myeloma

      • Patients must have active disease requiring treatment (Durie-Salmon stage I-III)

    • Acute myeloid leukemia

      • Must have < 10% bone marrow blasts and no circulating blasts

    • Myelodysplastic syndrome (MDS)

      • MDS as define by WHO criteria
      • Must have < 10% marrow blasts

  • Relapsed or progressive disease or myelodysplasia ≥ 6 months after prior high-dose chemotherapy with autologous hematopoietic cell support

    • Prior syngeneic transplantation allowed

  • Healthy donor meeting one of the following criteria:

    • HLA-identical sibling (6/6)

      • Serologic typing for class I (A, B) and molecular typing for class II (DRB1) required

    • 8/8 matched-unrelated donor

      • Molecular identity at HLA A, B, C, and DRB1 by high-resolution typing required
    • No syngeneic donors

PATIENT CHARACTERISTICS:

  • Creatinine clearance ≥ 40 mL/min
  • Total bilirubin ≤ 2 mg/dL
  • AST ≤ 3 times upper limit of normal
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • DLCO ≥ 40% with no symptomatic pulmonary disease
  • LVEF ≥ 30% by MUGA or ECHO
  • No uncontrolled diabetes mellitus or active serious infection
  • No known hypersensitivity to E.coli-derived products
  • No HIV infection

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • At least 4 weeks should elapse between prior standard cytotoxic chemotherapy, radiation therapy, or surgery and the planned start of the preparative regimen on day -7

Sites / Locations

  • Tunnell Cancer Center at Beebe Medical Center
  • CCOP - Christiana Care Health Services
  • Florida Hospital Cancer Institute at Florida Hospital Orlando
  • Greenebaum Cancer Center at University of Maryland Medical Center
  • Union Hospital of Cecil County
  • Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
  • Cancer Institute of New Jersey at Cooper - Voorhees
  • New York Weill Cornell Cancer Center at Cornell University
  • Wake Forest University Comprehensive Cancer Center
  • Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment

Arm Description

Matched-unrelated donor: Patients receive antithymocyte globulin, tacrolimus, and methotrexate as in HLA-identical donor regimen. Patients also receive oral mycophenolate mofetil twice daily on days 0 to 60. Allogeneic Stem Cell Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation on days 0 and 1. Patients then receive filgrastim subcutaneously daily beginning on day 7 and continuing until blood counts recover. Donor Lymphocyte Infusion (DLI): After day 180 (or day 210 for patients without an HLA-identical donor), patients with stable or progressive disease and no active GVHD may receive up to 3 DLIs every 8 weeks. Blood samples are collected at baseline and then periodically during study therapy for pharmacokinetic studies. After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for up to 5½ years.

Outcomes

Primary Outcome Measures

Event-free Survival (EFS)
EFS was defined as the date of transplant to date of progression or develop myelodysplasia after autologous transplant. EFS was estimated using the Kaplan Meier method.
Comparison of EFS Distribution to That of CALGB-100002
EFS distributions between CALGB-100002 and this study will be compared using the two-sample log-rank test.

Secondary Outcome Measures

Complete Response Rate
Complete response (CR) rate is reported as the percentage of participants who achieved a CR.
Overall Survival
Overall survival (OS) was defined as the transplant from registration to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% confidence interval (CI) was estimated using the Kaplan Meier method.
Rate of Opportunistic Infections
Percent of participants who have an opportunistic (viral, bacterial and fungal) infection in the first year following transplant.

Full Information

First Posted
May 5, 2010
Last Updated
February 6, 2017
Sponsor
Alliance for Clinical Trials in Oncology
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT01118013
Brief Title
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Official Title
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Terminated
Study Start Date
December 2010 (undefined)
Primary Completion Date
March 2012 (Actual)
Study Completion Date
August 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alliance for Clinical Trials in Oncology
Collaborators
National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
RATIONALE: Giving chemotherapy, such as busulfan and fludarabine phosphate, before a peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving methotrexate, tacrolimus, and antithymocyte globulin before and after the transplant may stop this from happening. Once the donated stem cells begin working, the patient's immune system may see the remaining cancer cells as not belonging in the patient's body and destroy them (called graft-versus-tumor effect). Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) may boost this effect. PURPOSE: This phase II trial is studying how well donor stem cell transplant works in treating patients with relapsed hematologic malignancies or secondary myelodysplasia previously treated with high-dose chemotherapy and autologous stem cell transplant .
Detailed Description
OBJECTIVES: Primary To demonstrate the efficacy of performing reduced-intensity conditioning allogeneic hematopoietic cell transplantation in patients with relapsed hematologic malignancies or secondary myelodysplasia after completion of prior high-dose chemotherapy and autologous hematopoietic stem cell transplantation. To compare the strategy of this regimen with the strategy used in CALGB-100002. Secondary To describe the response rate at 6 and 12 months in patients treated with this regimen. To describe the time-to-progression in patients treated with this regimen. To determine the ability to use pharmacokinetic-directed busulfan to achieve AUC within 20% of target AUC in > 80% of patients. To determine percent of donor chimerism in T-cell, myeloid and B-cell populations achieved with this regimen compared with CALGB-100002. To determine the risk of acute and chronic graft-versus-host disease and other toxicities of this regimen in these patients. To describe the overall survival and disease-free survival of patients treated on this regimen. To determine the rate of viral, bacterial, and fungal opportunistic infections occurring in the first year after transplantation compared with CALGB-100002. OUTLINE: This is a multicenter study. Preparative Regimen: Busulfan test dose: Patients receive busulfan IV over 45 minutes once during days -14 and -9. Busulfan treatment dose: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and busulfan IV over 3 hours on days -6 to -3. Graft-vs-Host Disease (GVHD) Prophylaxis: HLA-identical donor: Patients receive antithymocyte globulin IV over 6-10 hours on days -6 to -5; oral tacrolimus twice daily on days -2 to 90 followed by a taper* as tolerated until day 150 or 180; and methotrexate IV on days 1, 3, and 6. NOTE: * Tacrolimus may be tapered on days 60-90 if donor chimerism of CD3+ cells is < 50% at day 60 or patient has progressive disease. Matched-unrelated donor: Patients receive antithymocyte globulin, tacrolimus, and methotrexate as in HLA-identical donor regimen. Patients also receive oral mycophenolate mofetil twice daily on days 0 to 60. Allogeneic Stem Cell Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation on days 0 and 1. Patients then receive filgrastim subcutaneously daily beginning on day 7 and continuing until blood counts recover. Donor Lymphocyte Infusion (DLI): After day 180 (or day 210 for patients without an HLA-identical donor), patients with stable or progressive disease and no active GVHD may receive up to 3 DLIs every 8 weeks. Blood samples are collected at baseline and then periodically during study therapy for pharmacokinetic studies. After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for up to 5½ years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Keywords
adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), juvenile myelomonocytic leukemia, prolymphocytic leukemia, recurrent adult acute myeloid leukemia, recurrent adult T-cell leukemia/lymphoma, recurrent childhood acute myeloid leukemia, refractory chronic lymphocytic leukemia, recurrent adult Hodgkin lymphoma, recurrent adult Burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade III lymphomatoid granulomatosis, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent childhood grade III lymphomatoid granulomatosis, recurrent childhood large cell lymphoma, recurrent childhood lymphoblastic lymphoma, recurrent childhood small noncleaved cell lymphoma, recurrent cutaneous T-cell non-Hodgkin lymphoma, recurrent mycosis fungoides/Sezary syndrome, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, recurrent/refractory childhood Hodgkin lymphoma, childhood diffuse large cell lymphoma, childhood grade III lymphomatoid granulomatosis, childhood immunoblastic large cell lymphoma, childhood nasal type extranodal NK/T-cell lymphoma, post-transplant lymphoproliferative disorder, stage I multiple myeloma, stage II multiple myeloma, stage III multiple myeloma, refractory multiple myeloma, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, childhood myelodysplastic syndromes, recurrent childhood anaplastic large cell lymphoma, adult acute myelomonocytic leukemia (M4), childhood acute myelomonocytic leukemia (M4), adult acute minimally differentiated myeloid leukemia (M0), childhood acute minimally differentiated myeloid leukemia (M0), adult acute myeloblastic leukemia without maturation (M1), childhood acute myeloblastic leukemia without maturation (M1), adult acute myeloblastic leukemia with maturation (M2), childhood acute myeloblastic leukemia with maturation (M2), adult acute promyelocytic leukemia (M3), childhood acute promyelocytic leukemia (M3), adult acute monoblastic leukemia (M5a), adult acute monocytic leukemia (M5b), childhood acute monoblastic leukemia (M5a), childhood acute monocytic leukemia (M5b), adult erythroleukemia (M6a), adult pure erythroid leukemia (M6b), childhood acute erythroleukemia (M6), adult acute megakaryoblastic leukemia (M7), childhood acute megakaryocytic leukemia (M7), childhood Burkitt lymphoma, atypical chronic myeloid leukemia, BCR-ABL1 negative, chronic myelomonocytic leukemia, cutaneous B-cell non-Hodgkin lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma, myelodysplastic/myeloproliferative neoplasm, unclassifiable

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
6 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
Matched-unrelated donor: Patients receive antithymocyte globulin, tacrolimus, and methotrexate as in HLA-identical donor regimen. Patients also receive oral mycophenolate mofetil twice daily on days 0 to 60. Allogeneic Stem Cell Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation on days 0 and 1. Patients then receive filgrastim subcutaneously daily beginning on day 7 and continuing until blood counts recover. Donor Lymphocyte Infusion (DLI): After day 180 (or day 210 for patients without an HLA-identical donor), patients with stable or progressive disease and no active GVHD may receive up to 3 DLIs every 8 weeks. Blood samples are collected at baseline and then periodically during study therapy for pharmacokinetic studies. After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for up to 5½ years.
Intervention Type
Biological
Intervention Name(s)
anti-thymocyte globulin
Intervention Type
Biological
Intervention Name(s)
donor lymphocytes
Intervention Type
Biological
Intervention Name(s)
filgrastim
Intervention Type
Biological
Intervention Name(s)
therapeutic allogeneic lymphocytes
Intervention Type
Drug
Intervention Name(s)
busulfan
Intervention Type
Drug
Intervention Name(s)
fludarabine phosphate
Intervention Type
Drug
Intervention Name(s)
methotrexate
Intervention Type
Drug
Intervention Name(s)
mycophenolate mofetil
Intervention Type
Drug
Intervention Name(s)
tacrolimus
Intervention Type
Other
Intervention Name(s)
reduced-intensity transplant conditioning procedure
Intervention Type
Procedure
Intervention Name(s)
allogeneic hematopoietic stem cell transplantation
Intervention Type
Procedure
Intervention Name(s)
peripheral blood stem cell transplantation
Primary Outcome Measure Information:
Title
Event-free Survival (EFS)
Description
EFS was defined as the date of transplant to date of progression or develop myelodysplasia after autologous transplant. EFS was estimated using the Kaplan Meier method.
Time Frame
Duration of study (up to 5.5 years)
Title
Comparison of EFS Distribution to That of CALGB-100002
Description
EFS distributions between CALGB-100002 and this study will be compared using the two-sample log-rank test.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Complete Response Rate
Description
Complete response (CR) rate is reported as the percentage of participants who achieved a CR.
Time Frame
Up to 5.5 years
Title
Overall Survival
Description
Overall survival (OS) was defined as the transplant from registration to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% confidence interval (CI) was estimated using the Kaplan Meier method.
Time Frame
Up to 5.5 years
Title
Rate of Opportunistic Infections
Description
Percent of participants who have an opportunistic (viral, bacterial and fungal) infection in the first year following transplant.
Time Frame
1 year post transplant

10. Eligibility

Sex
All
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed hematologic malignancies: Chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL) Absolute lymphocytosis of > 5,000/μL Lymphocytes must appear morphologically mature with < 55% prolymphocytes (CLL) Patients with > 55% prolymphocytes are considered as having PLL Lymphocyte phenotype with expression of CD20, CD19, and CD5 (CLL) Non-Hodgkin lymphoma Any WHO classification of histologic subtype Core biopsies acceptable for primary diagnosis and immunophenotyping Bone marrow biopsies as sole means of diagnosis not allowed for follicular lymphoma Hodgkin lymphoma Any WHO classification of histologic subtype Core biopsies acceptable for primary diagnosis and immunophenotyping Bone marrow biopsy is required Multiple myeloma Patients must have active disease requiring treatment (Durie-Salmon stage I-III) Acute myeloid leukemia Must have < 10% bone marrow blasts and no circulating blasts Myelodysplastic syndrome (MDS) MDS as define by WHO criteria Must have < 10% marrow blasts Relapsed or progressive disease or myelodysplasia ≥ 6 months after prior high-dose chemotherapy with autologous hematopoietic cell support Prior syngeneic transplantation allowed Healthy donor meeting one of the following criteria: HLA-identical sibling (6/6) Serologic typing for class I (A, B) and molecular typing for class II (DRB1) required 8/8 matched-unrelated donor Molecular identity at HLA A, B, C, and DRB1 by high-resolution typing required No syngeneic donors PATIENT CHARACTERISTICS: Creatinine clearance ≥ 40 mL/min Total bilirubin ≤ 2 mg/dL AST ≤ 3 times upper limit of normal Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception DLCO ≥ 40% with no symptomatic pulmonary disease LVEF ≥ 30% by MUGA or ECHO No uncontrolled diabetes mellitus or active serious infection No known hypersensitivity to E.coli-derived products No HIV infection PRIOR CONCURRENT THERAPY: See Disease Characteristics At least 4 weeks should elapse between prior standard cytotoxic chemotherapy, radiation therapy, or surgery and the planned start of the preparative regimen on day -7
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Asad Bashey, MD, PhD
Organizational Affiliation
Blood and Marrow Transplant Group of Georgia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tunnell Cancer Center at Beebe Medical Center
City
Lewes
State/Province
Delaware
ZIP/Postal Code
19958
Country
United States
Facility Name
CCOP - Christiana Care Health Services
City
Newark
State/Province
Delaware
ZIP/Postal Code
19713
Country
United States
Facility Name
Florida Hospital Cancer Institute at Florida Hospital Orlando
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803-1273
Country
United States
Facility Name
Greenebaum Cancer Center at University of Maryland Medical Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
Union Hospital of Cecil County
City
Elkton MD
State/Province
Maryland
ZIP/Postal Code
21921
Country
United States
Facility Name
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Cancer Institute of New Jersey at Cooper - Voorhees
City
Voorhees
State/Province
New Jersey
ZIP/Postal Code
08043
Country
United States
Facility Name
New York Weill Cornell Cancer Center at Cornell University
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Wake Forest University Comprehensive Cancer Center
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157-1096
Country
United States
Facility Name
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210-1240
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

We'll reach out to this number within 24 hrs